TP53 and cancer: WB-MRI has been separately studied in a number of centres across North America, Canada and Europe, and a meta-analysis of the data from 13 studies in 578 TP53 carriers from six countries, including the UK SIGNIFY study, evidences a 7% (95% CI 5% to 9%) new cancer detection rate, with the majority of cancers being detected at a sufficiently early stage to allow treatment with curative intent.11 12